nodes	percent_of_prediction	percent_of_DWPC	metapath
Risedronate—PTGS2—esophageal cancer	0.709	1	CbGaD
Risedronate—PTGS2—Cisplatin—esophageal cancer	0.12	1	CbGbCtD
Risedronate—Malabsorption—Methotrexate—esophageal cancer	0.00435	0.0384	CcSEcCtD
Risedronate—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—ALOX15—esophageal cancer	0.00391	0.0868	CbGpPWpGaD
Risedronate—Duodenitis—Capecitabine—esophageal cancer	0.00288	0.0254	CcSEcCtD
Risedronate—Zoledronate—CA2—esophageal cancer	0.00278	1	CrCbGaD
Risedronate—Abdominal pain lower—Capecitabine—esophageal cancer	0.00267	0.0235	CcSEcCtD
Risedronate—Gastrointestinal tract irritation—Capecitabine—esophageal cancer	0.00237	0.0209	CcSEcCtD
Risedronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—esophageal cancer	0.00175	0.0389	CbGpPWpGaD
Risedronate—Rectal disorder—Capecitabine—esophageal cancer	0.00173	0.0152	CcSEcCtD
Risedronate—Anorectal disorder—Capecitabine—esophageal cancer	0.00161	0.0142	CcSEcCtD
Risedronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—esophageal cancer	0.00152	0.0337	CbGpPWpGaD
Risedronate—Gastric ulcer—Capecitabine—esophageal cancer	0.00146	0.0129	CcSEcCtD
Risedronate—Haemorrhoids—Capecitabine—esophageal cancer	0.00144	0.0127	CcSEcCtD
Risedronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—FKBP1A—esophageal cancer	0.00143	0.0317	CbGpPWpGaD
Risedronate—Infection—Carboplatin—esophageal cancer	0.00139	0.0123	CcSEcCtD
Risedronate—FDPS—bronchus—esophageal cancer	0.00139	0.144	CbGeAlD
Risedronate—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS1—esophageal cancer	0.00138	0.0306	CbGpPWpGaD
Risedronate—FDPS—smooth muscle tissue—esophageal cancer	0.00136	0.141	CbGeAlD
Risedronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—CYP2A6—esophageal cancer	0.00131	0.029	CbGpPWpGaD
Risedronate—PTGS2—Eicosanoid Synthesis—ALOX15—esophageal cancer	0.00129	0.0286	CbGpPWpGaD
Risedronate—FDPS—trachea—esophageal cancer	0.00124	0.129	CbGeAlD
Risedronate—Hypercalcaemia—Capecitabine—esophageal cancer	0.00122	0.0108	CcSEcCtD
Risedronate—Neuralgia—Capecitabine—esophageal cancer	0.00122	0.0108	CcSEcCtD
Risedronate—Ulcer—Cisplatin—esophageal cancer	0.00122	0.0107	CcSEcCtD
Risedronate—Pain—Carboplatin—esophageal cancer	0.0012	0.0105	CcSEcCtD
Risedronate—FDPS—Activation of gene expression by SREBF (SREBP)—CREBBP—esophageal cancer	0.00116	0.0258	CbGpPWpGaD
Risedronate—Herpes zoster—Capecitabine—esophageal cancer	0.00113	0.00993	CcSEcCtD
Risedronate—Body temperature increased—Carboplatin—esophageal cancer	0.00111	0.00975	CcSEcCtD
Risedronate—Otitis media—Capecitabine—esophageal cancer	0.00109	0.0096	CcSEcCtD
Risedronate—Multiple fractures—Methotrexate—esophageal cancer	0.00109	0.00958	CcSEcCtD
Risedronate—Fracture—Methotrexate—esophageal cancer	0.00109	0.00958	CcSEcCtD
Risedronate—PTGS2—Overview of nanoparticle effects—PTGS1—esophageal cancer	0.00108	0.0239	CbGpPWpGaD
Risedronate—FDPS—digestive system—esophageal cancer	0.00107	0.111	CbGeAlD
Risedronate—Polyp—Methotrexate—esophageal cancer	0.00104	0.00915	CcSEcCtD
Risedronate—Contusion—Capecitabine—esophageal cancer	0.000971	0.00857	CcSEcCtD
Risedronate—Cyst—Methotrexate—esophageal cancer	0.000944	0.00833	CcSEcCtD
Risedronate—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.000938	0.00828	CcSEcCtD
Risedronate—FDPS—Regulation of cholesterol biosynthesis by SREBP (SREBF)—CREBBP—esophageal cancer	0.000928	0.0206	CbGpPWpGaD
Risedronate—Hypocalcaemia—Capecitabine—esophageal cancer	0.000926	0.00817	CcSEcCtD
Risedronate—Ulcer—Capecitabine—esophageal cancer	0.000896	0.0079	CcSEcCtD
Risedronate—PTGS2—Eicosanoid Synthesis—PTGS1—esophageal cancer	0.000895	0.0199	CbGpPWpGaD
Risedronate—FDPS—lung—esophageal cancer	0.000894	0.093	CbGeAlD
Risedronate—Cataract—Capecitabine—esophageal cancer	0.00089	0.00785	CcSEcCtD
Risedronate—Bone pain—Capecitabine—esophageal cancer	0.000885	0.0078	CcSEcCtD
Risedronate—Inflammation—Capecitabine—esophageal cancer	0.000874	0.00771	CcSEcCtD
Risedronate—Neck pain—Capecitabine—esophageal cancer	0.000858	0.00757	CcSEcCtD
Risedronate—Herpes zoster—Methotrexate—esophageal cancer	0.000838	0.00739	CcSEcCtD
Risedronate—Influenza like illness—Capecitabine—esophageal cancer	0.000823	0.00726	CcSEcCtD
Risedronate—Colitis—Capecitabine—esophageal cancer	0.000814	0.00718	CcSEcCtD
Risedronate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC52A3—esophageal cancer	0.000802	0.0178	CbGpPWpGaD
Risedronate—PTGS2—Overview of nanoparticle effects—HMOX1—esophageal cancer	0.000787	0.0175	CbGpPWpGaD
Risedronate—Dry eye—Capecitabine—esophageal cancer	0.000783	0.00691	CcSEcCtD
Risedronate—Oesophagitis—Capecitabine—esophageal cancer	0.000774	0.00683	CcSEcCtD
Risedronate—Ecchymosis—Capecitabine—esophageal cancer	0.000766	0.00676	CcSEcCtD
Risedronate—Neoplasm—Capecitabine—esophageal cancer	0.000766	0.00676	CcSEcCtD
Risedronate—Breast disorder—Cisplatin—esophageal cancer	0.000754	0.00665	CcSEcCtD
Risedronate—PTGS2—Prostaglandin Synthesis and Regulation—PTGS1—esophageal cancer	0.000749	0.0166	CbGpPWpGaD
Risedronate—Nasopharyngitis—Cisplatin—esophageal cancer	0.000746	0.00658	CcSEcCtD
Risedronate—PTGS2—Prostaglandin Synthesis and Regulation—ANXA1—esophageal cancer	0.000734	0.0163	CbGpPWpGaD
Risedronate—PTGS2—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.000718	0.0159	CbGpPWpGaD
Risedronate—PTGS2—Overview of nanoparticle effects—BAX—esophageal cancer	0.000715	0.0159	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—CA1—esophageal cancer	0.000702	0.0156	CbGpPWpGaD
Risedronate—Bone disorder—Methotrexate—esophageal cancer	0.000699	0.00616	CcSEcCtD
Risedronate—Gastroenteritis—Capecitabine—esophageal cancer	0.000694	0.00612	CcSEcCtD
Risedronate—Abdominal discomfort—Cisplatin—esophageal cancer	0.000692	0.0061	CcSEcCtD
Risedronate—Glossitis—Methotrexate—esophageal cancer	0.000685	0.00604	CcSEcCtD
Risedronate—PTGS2—Selenium Micronutrient Network—PRDX1—esophageal cancer	0.000676	0.015	CbGpPWpGaD
Risedronate—PTGS2—Selenium Micronutrient Network—PRDX2—esophageal cancer	0.000676	0.015	CbGpPWpGaD
Risedronate—Ulcer—Methotrexate—esophageal cancer	0.000667	0.00588	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—NFE2L2—esophageal cancer	0.000652	0.0145	CbGpPWpGaD
Risedronate—Inflammation—Methotrexate—esophageal cancer	0.00065	0.00574	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000634	0.0141	CbGpPWpGaD
Risedronate—Arthritis—Capecitabine—esophageal cancer	0.000633	0.00558	CcSEcCtD
Risedronate—Conjunctivitis—Cisplatin—esophageal cancer	0.000625	0.00551	CcSEcCtD
Risedronate—Cystitis noninfective—Methotrexate—esophageal cancer	0.000616	0.00544	CcSEcCtD
Risedronate—Osteoarthritis—Capecitabine—esophageal cancer	0.000615	0.00543	CcSEcCtD
Risedronate—Pain in extremity—Capecitabine—esophageal cancer	0.000615	0.00543	CcSEcCtD
Risedronate—FDPS—lymph node—esophageal cancer	0.000611	0.0636	CbGeAlD
Risedronate—Cystitis—Methotrexate—esophageal cancer	0.000609	0.00537	CcSEcCtD
Risedronate—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000608	0.00537	CcSEcCtD
Risedronate—PTGS2—S1P1 pathway—KDR—esophageal cancer	0.000591	0.0131	CbGpPWpGaD
Risedronate—Ecchymosis—Methotrexate—esophageal cancer	0.00057	0.00503	CcSEcCtD
Risedronate—Neoplasm—Methotrexate—esophageal cancer	0.00057	0.00503	CcSEcCtD
Risedronate—Bladder pain—Methotrexate—esophageal cancer	0.00057	0.00503	CcSEcCtD
Risedronate—Urinary tract disorder—Cisplatin—esophageal cancer	0.00057	0.00503	CcSEcCtD
Risedronate—Liver function test abnormal—Capecitabine—esophageal cancer	0.000568	0.00501	CcSEcCtD
Risedronate—Connective tissue disorder—Cisplatin—esophageal cancer	0.000567	0.005	CcSEcCtD
Risedronate—Urethral disorder—Cisplatin—esophageal cancer	0.000566	0.00499	CcSEcCtD
Risedronate—Abdominal pain upper—Capecitabine—esophageal cancer	0.000562	0.00496	CcSEcCtD
Risedronate—Breast disorder—Capecitabine—esophageal cancer	0.000556	0.0049	CcSEcCtD
Risedronate—Nasopharyngitis—Capecitabine—esophageal cancer	0.00055	0.00485	CcSEcCtD
Risedronate—Gastritis—Capecitabine—esophageal cancer	0.000545	0.0048	CcSEcCtD
Risedronate—Muscular weakness—Capecitabine—esophageal cancer	0.000543	0.00479	CcSEcCtD
Risedronate—Eye disorder—Cisplatin—esophageal cancer	0.00054	0.00476	CcSEcCtD
Risedronate—PTGS2—epithelium—esophageal cancer	0.000539	0.0561	CbGeAlD
Risedronate—Tinnitus—Cisplatin—esophageal cancer	0.000538	0.00475	CcSEcCtD
Risedronate—Cardiac disorder—Cisplatin—esophageal cancer	0.000536	0.00473	CcSEcCtD
Risedronate—Abdominal distension—Capecitabine—esophageal cancer	0.000535	0.00472	CcSEcCtD
Risedronate—Influenza—Capecitabine—esophageal cancer	0.000532	0.00469	CcSEcCtD
Risedronate—Asthma—Capecitabine—esophageal cancer	0.000532	0.00469	CcSEcCtD
Risedronate—PTGS2—bronchus—esophageal cancer	0.000531	0.0552	CbGeAlD
Risedronate—Immune system disorder—Cisplatin—esophageal cancer	0.000522	0.0046	CcSEcCtD
Risedronate—Mediastinal disorder—Cisplatin—esophageal cancer	0.00052	0.00459	CcSEcCtD
Risedronate—PTGS2—smooth muscle tissue—esophageal cancer	0.000519	0.0541	CbGeAlD
Risedronate—Angina pectoris—Capecitabine—esophageal cancer	0.000518	0.00457	CcSEcCtD
Risedronate—Arrhythmia—Cisplatin—esophageal cancer	0.000516	0.00455	CcSEcCtD
Risedronate—Bronchitis—Capecitabine—esophageal cancer	0.000511	0.00451	CcSEcCtD
Risedronate—Abdominal discomfort—Capecitabine—esophageal cancer	0.00051	0.0045	CcSEcCtD
Risedronate—Malnutrition—Cisplatin—esophageal cancer	0.000503	0.00443	CcSEcCtD
Risedronate—PTGS2—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000498	0.011	CbGpPWpGaD
Risedronate—Flatulence—Cisplatin—esophageal cancer	0.000495	0.00437	CcSEcCtD
Risedronate—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000494	0.00436	CcSEcCtD
Risedronate—Muscle spasms—Cisplatin—esophageal cancer	0.000483	0.00426	CcSEcCtD
Risedronate—Pneumonia—Capecitabine—esophageal cancer	0.000477	0.00421	CcSEcCtD
Risedronate—PTGS2—trachea—esophageal cancer	0.000477	0.0496	CbGeAlD
Risedronate—Infestation NOS—Capecitabine—esophageal cancer	0.000474	0.00418	CcSEcCtD
Risedronate—Infestation—Capecitabine—esophageal cancer	0.000474	0.00418	CcSEcCtD
Risedronate—Depression—Capecitabine—esophageal cancer	0.000473	0.00417	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—FKBP1A—esophageal cancer	0.000465	0.0103	CbGpPWpGaD
Risedronate—Anaemia—Cisplatin—esophageal cancer	0.000465	0.0041	CcSEcCtD
Risedronate—Conjunctivitis—Capecitabine—esophageal cancer	0.000461	0.00407	CcSEcCtD
Risedronate—Urinary tract infection—Capecitabine—esophageal cancer	0.000461	0.00407	CcSEcCtD
Risedronate—Osteoarthritis—Methotrexate—esophageal cancer	0.000458	0.00404	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—CYP1B1—esophageal cancer	0.000452	0.01	CbGpPWpGaD
Risedronate—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000448	0.00396	CcSEcCtD
Risedronate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—GSTO1—esophageal cancer	0.00044	0.00975	CbGpPWpGaD
Risedronate—PTGS2—Overview of nanoparticle effects—BCL2—esophageal cancer	0.000435	0.00965	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000428	0.0095	CbGpPWpGaD
Risedronate—Myalgia—Cisplatin—esophageal cancer	0.000428	0.00377	CcSEcCtD
Risedronate—Haemoglobin—Capecitabine—esophageal cancer	0.000428	0.00377	CcSEcCtD
Risedronate—Rhinitis—Capecitabine—esophageal cancer	0.000427	0.00376	CcSEcCtD
Risedronate—Anxiety—Cisplatin—esophageal cancer	0.000426	0.00376	CcSEcCtD
Risedronate—Haemorrhage—Capecitabine—esophageal cancer	0.000426	0.00375	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000425	0.00375	CcSEcCtD
Risedronate—PTGS2—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000423	0.00938	CbGpPWpGaD
Risedronate—Liver function test abnormal—Methotrexate—esophageal cancer	0.000423	0.00373	CcSEcCtD
Risedronate—Pharyngitis—Capecitabine—esophageal cancer	0.000422	0.00373	CcSEcCtD
Risedronate—Urinary tract disorder—Capecitabine—esophageal cancer	0.00042	0.00371	CcSEcCtD
Risedronate—Oedema peripheral—Capecitabine—esophageal cancer	0.000419	0.0037	CcSEcCtD
Risedronate—Connective tissue disorder—Capecitabine—esophageal cancer	0.000418	0.00369	CcSEcCtD
Risedronate—Urethral disorder—Capecitabine—esophageal cancer	0.000417	0.00368	CcSEcCtD
Risedronate—Breast disorder—Methotrexate—esophageal cancer	0.000414	0.00365	CcSEcCtD
Risedronate—PTGS2—digestive system—esophageal cancer	0.00041	0.0427	CbGeAlD
Risedronate—Infection—Cisplatin—esophageal cancer	0.000408	0.00359	CcSEcCtD
Risedronate—Nervous system disorder—Cisplatin—esophageal cancer	0.000402	0.00355	CcSEcCtD
Risedronate—Skin disorder—Cisplatin—esophageal cancer	0.000398	0.00351	CcSEcCtD
Risedronate—Eye disorder—Capecitabine—esophageal cancer	0.000398	0.00351	CcSEcCtD
Risedronate—Tinnitus—Capecitabine—esophageal cancer	0.000397	0.0035	CcSEcCtD
Risedronate—Asthma—Methotrexate—esophageal cancer	0.000396	0.00349	CcSEcCtD
Risedronate—Cardiac disorder—Capecitabine—esophageal cancer	0.000395	0.00348	CcSEcCtD
Risedronate—Angiopathy—Capecitabine—esophageal cancer	0.000386	0.00341	CcSEcCtD
Risedronate—Immune system disorder—Capecitabine—esophageal cancer	0.000384	0.00339	CcSEcCtD
Risedronate—Mediastinal disorder—Capecitabine—esophageal cancer	0.000384	0.00338	CcSEcCtD
Risedronate—Arrhythmia—Capecitabine—esophageal cancer	0.00038	0.00335	CcSEcCtD
Risedronate—Abdominal discomfort—Methotrexate—esophageal cancer	0.000379	0.00335	CcSEcCtD
Risedronate—FDPS—SREBP signalling—PIK3CA—esophageal cancer	0.000379	0.0084	CbGpPWpGaD
Risedronate—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000374	0.0033	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000374	0.00829	CbGpPWpGaD
Risedronate—Mental disorder—Capecitabine—esophageal cancer	0.000373	0.00329	CcSEcCtD
Risedronate—Malnutrition—Capecitabine—esophageal cancer	0.000371	0.00327	CcSEcCtD
Risedronate—Paraesthesia—Cisplatin—esophageal cancer	0.000368	0.00325	CcSEcCtD
Risedronate—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000368	0.00325	CcSEcCtD
Risedronate—Dyspnoea—Cisplatin—esophageal cancer	0.000366	0.00323	CcSEcCtD
Risedronate—Flatulence—Capecitabine—esophageal cancer	0.000365	0.00322	CcSEcCtD
Risedronate—Back pain—Capecitabine—esophageal cancer	0.000358	0.00316	CcSEcCtD
Risedronate—Muscle spasms—Capecitabine—esophageal cancer	0.000356	0.00314	CcSEcCtD
Risedronate—Pneumonia—Methotrexate—esophageal cancer	0.000355	0.00313	CcSEcCtD
Risedronate—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000354	0.00312	CcSEcCtD
Risedronate—Infestation—Methotrexate—esophageal cancer	0.000353	0.00311	CcSEcCtD
Risedronate—Infestation NOS—Methotrexate—esophageal cancer	0.000353	0.00311	CcSEcCtD
Risedronate—Depression—Methotrexate—esophageal cancer	0.000352	0.0031	CcSEcCtD
Risedronate—Pain—Cisplatin—esophageal cancer	0.000351	0.00309	CcSEcCtD
Risedronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—esophageal cancer	0.000345	0.00765	CbGpPWpGaD
Risedronate—Conjunctivitis—Methotrexate—esophageal cancer	0.000343	0.00303	CcSEcCtD
Risedronate—PTGS2—lung—esophageal cancer	0.000343	0.0356	CbGeAlD
Risedronate—Anaemia—Capecitabine—esophageal cancer	0.000342	0.00302	CcSEcCtD
Risedronate—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000334	0.00294	CcSEcCtD
Risedronate—Vertigo—Capecitabine—esophageal cancer	0.000333	0.00294	CcSEcCtD
Risedronate—Syncope—Capecitabine—esophageal cancer	0.000332	0.00293	CcSEcCtD
Risedronate—FDPS—Metabolism—SLC52A3—esophageal cancer	0.000332	0.00737	CbGpPWpGaD
Risedronate—FDPS—Metabolism—BLVRB—esophageal cancer	0.000332	0.00737	CbGpPWpGaD
Risedronate—Loss of consciousness—Capecitabine—esophageal cancer	0.000326	0.00287	CcSEcCtD
Risedronate—Body temperature increased—Cisplatin—esophageal cancer	0.000324	0.00286	CcSEcCtD
Risedronate—Cough—Capecitabine—esophageal cancer	0.000323	0.00285	CcSEcCtD
Risedronate—Hypertension—Capecitabine—esophageal cancer	0.00032	0.00282	CcSEcCtD
Risedronate—Haemoglobin—Methotrexate—esophageal cancer	0.000318	0.00281	CcSEcCtD
Risedronate—Haemorrhage—Methotrexate—esophageal cancer	0.000317	0.00279	CcSEcCtD
Risedronate—PTGS2—Selenium Micronutrient Network—PTGS1—esophageal cancer	0.000317	0.00702	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000316	0.00702	CbGpPWpGaD
Risedronate—Chest pain—Capecitabine—esophageal cancer	0.000315	0.00278	CcSEcCtD
Risedronate—Arthralgia—Capecitabine—esophageal cancer	0.000315	0.00278	CcSEcCtD
Risedronate—Myalgia—Capecitabine—esophageal cancer	0.000315	0.00278	CcSEcCtD
Risedronate—Pharyngitis—Methotrexate—esophageal cancer	0.000314	0.00277	CcSEcCtD
Risedronate—Anxiety—Capecitabine—esophageal cancer	0.000314	0.00277	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000313	0.00276	CcSEcCtD
Risedronate—Urinary tract disorder—Methotrexate—esophageal cancer	0.000313	0.00276	CcSEcCtD
Risedronate—Urethral disorder—Methotrexate—esophageal cancer	0.000311	0.00274	CcSEcCtD
Risedronate—Dry mouth—Capecitabine—esophageal cancer	0.000309	0.00272	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—LGALS3—esophageal cancer	0.000305	0.00675	CbGpPWpGaD
Risedronate—Hypersensitivity—Cisplatin—esophageal cancer	0.000302	0.00267	CcSEcCtD
Risedronate—Infection—Capecitabine—esophageal cancer	0.0003	0.00265	CcSEcCtD
Risedronate—Shock—Capecitabine—esophageal cancer	0.000298	0.00262	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000297	0.00658	CbGpPWpGaD
Risedronate—Nervous system disorder—Capecitabine—esophageal cancer	0.000297	0.00262	CcSEcCtD
Risedronate—Eye disorder—Methotrexate—esophageal cancer	0.000296	0.00261	CcSEcCtD
Risedronate—Tinnitus—Methotrexate—esophageal cancer	0.000295	0.00261	CcSEcCtD
Risedronate—Asthenia—Cisplatin—esophageal cancer	0.000294	0.0026	CcSEcCtD
Risedronate—Cardiac disorder—Methotrexate—esophageal cancer	0.000294	0.00259	CcSEcCtD
Risedronate—Skin disorder—Capecitabine—esophageal cancer	0.000294	0.00259	CcSEcCtD
Risedronate—Angiopathy—Methotrexate—esophageal cancer	0.000287	0.00254	CcSEcCtD
Risedronate—Immune system disorder—Methotrexate—esophageal cancer	0.000286	0.00252	CcSEcCtD
Risedronate—Mediastinal disorder—Methotrexate—esophageal cancer	0.000286	0.00252	CcSEcCtD
Risedronate—FDPS—Metabolism—SLC10A2—esophageal cancer	0.000282	0.00626	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CA1—esophageal cancer	0.000282	0.00626	CbGpPWpGaD
Risedronate—Diarrhoea—Cisplatin—esophageal cancer	0.000281	0.00248	CcSEcCtD
Risedronate—Mental disorder—Methotrexate—esophageal cancer	0.000278	0.00245	CcSEcCtD
Risedronate—Malnutrition—Methotrexate—esophageal cancer	0.000276	0.00243	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000276	0.00243	CcSEcCtD
Risedronate—Insomnia—Capecitabine—esophageal cancer	0.000274	0.00241	CcSEcCtD
Risedronate—Paraesthesia—Capecitabine—esophageal cancer	0.000272	0.0024	CcSEcCtD
Risedronate—Dyspnoea—Capecitabine—esophageal cancer	0.00027	0.00238	CcSEcCtD
Risedronate—Back pain—Methotrexate—esophageal cancer	0.000267	0.00235	CcSEcCtD
Risedronate—Dyspepsia—Capecitabine—esophageal cancer	0.000266	0.00235	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—CXCL2—esophageal cancer	0.000264	0.00586	CbGpPWpGaD
Risedronate—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000261	0.0023	CcSEcCtD
Risedronate—Vomiting—Cisplatin—esophageal cancer	0.000261	0.0023	CcSEcCtD
Risedronate—Fatigue—Capecitabine—esophageal cancer	0.000261	0.0023	CcSEcCtD
Risedronate—Rash—Cisplatin—esophageal cancer	0.000259	0.00228	CcSEcCtD
Risedronate—Constipation—Capecitabine—esophageal cancer	0.000259	0.00228	CcSEcCtD
Risedronate—Pain—Capecitabine—esophageal cancer	0.000259	0.00228	CcSEcCtD
Risedronate—Dermatitis—Cisplatin—esophageal cancer	0.000258	0.00228	CcSEcCtD
Risedronate—FDPS—Metabolism—CA2—esophageal cancer	0.000258	0.00573	CbGpPWpGaD
Risedronate—Anaemia—Methotrexate—esophageal cancer	0.000255	0.00225	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000252	0.0056	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000248	0.0055	CbGpPWpGaD
Risedronate—Vertigo—Methotrexate—esophageal cancer	0.000248	0.00219	CcSEcCtD
Risedronate—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000247	0.00218	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000246	0.00545	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—ANXA1—esophageal cancer	0.000246	0.00544	CbGpPWpGaD
Risedronate—Nausea—Cisplatin—esophageal cancer	0.000244	0.00215	CcSEcCtD
Risedronate—Cough—Methotrexate—esophageal cancer	0.000241	0.00212	CcSEcCtD
Risedronate—Urticaria—Capecitabine—esophageal cancer	0.00024	0.00212	CcSEcCtD
Risedronate—FDPS—Metabolism—PLCE1—esophageal cancer	0.00024	0.00533	CbGpPWpGaD
Risedronate—FDPS—Metabolism—ADH7—esophageal cancer	0.00024	0.00533	CbGpPWpGaD
Risedronate—Body temperature increased—Capecitabine—esophageal cancer	0.000239	0.00211	CcSEcCtD
Risedronate—Abdominal pain—Capecitabine—esophageal cancer	0.000239	0.00211	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000237	0.00526	CbGpPWpGaD
Risedronate—Chest pain—Methotrexate—esophageal cancer	0.000235	0.00207	CcSEcCtD
Risedronate—Myalgia—Methotrexate—esophageal cancer	0.000235	0.00207	CcSEcCtD
Risedronate—Arthralgia—Methotrexate—esophageal cancer	0.000235	0.00207	CcSEcCtD
Risedronate—PTGS2—lymph node—esophageal cancer	0.000234	0.0244	CbGeAlD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000233	0.00206	CcSEcCtD
Risedronate—Infection—Methotrexate—esophageal cancer	0.000224	0.00197	CcSEcCtD
Risedronate—Hypersensitivity—Capecitabine—esophageal cancer	0.000223	0.00197	CcSEcCtD
Risedronate—Nervous system disorder—Methotrexate—esophageal cancer	0.000221	0.00195	CcSEcCtD
Risedronate—Skin disorder—Methotrexate—esophageal cancer	0.000219	0.00193	CcSEcCtD
Risedronate—Asthenia—Capecitabine—esophageal cancer	0.000217	0.00191	CcSEcCtD
Risedronate—PTGS2—Selenium Micronutrient Network—SOD2—esophageal cancer	0.000216	0.00479	CbGpPWpGaD
Risedronate—Pruritus—Capecitabine—esophageal cancer	0.000214	0.00189	CcSEcCtD
Risedronate—FDPS—Metabolism—ADH1B—esophageal cancer	0.000211	0.00467	CbGpPWpGaD
Risedronate—Diarrhoea—Capecitabine—esophageal cancer	0.000207	0.00182	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000205	0.00181	CcSEcCtD
Risedronate—Insomnia—Methotrexate—esophageal cancer	0.000204	0.0018	CcSEcCtD
Risedronate—Paraesthesia—Methotrexate—esophageal cancer	0.000202	0.00178	CcSEcCtD
Risedronate—FDPS—Metabolism—TYMP—esophageal cancer	0.000201	0.00446	CbGpPWpGaD
Risedronate—Dyspnoea—Methotrexate—esophageal cancer	0.000201	0.00177	CcSEcCtD
Risedronate—Dizziness—Capecitabine—esophageal cancer	0.0002	0.00176	CcSEcCtD
Risedronate—Dyspepsia—Methotrexate—esophageal cancer	0.000198	0.00175	CcSEcCtD
Risedronate—FDPS—Metabolism—CYP26A1—esophageal cancer	0.000196	0.00434	CbGpPWpGaD
Risedronate—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000194	0.00171	CcSEcCtD
Risedronate—Fatigue—Methotrexate—esophageal cancer	0.000194	0.00171	CcSEcCtD
Risedronate—Pain—Methotrexate—esophageal cancer	0.000193	0.0017	CcSEcCtD
Risedronate—Vomiting—Capecitabine—esophageal cancer	0.000192	0.0017	CcSEcCtD
Risedronate—FDPS—Metabolism—ALOX15—esophageal cancer	0.000191	0.00423	CbGpPWpGaD
Risedronate—Rash—Capecitabine—esophageal cancer	0.000191	0.00168	CcSEcCtD
Risedronate—Dermatitis—Capecitabine—esophageal cancer	0.00019	0.00168	CcSEcCtD
Risedronate—Headache—Capecitabine—esophageal cancer	0.000189	0.00167	CcSEcCtD
Risedronate—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000184	0.00162	CcSEcCtD
Risedronate—FDPS—Metabolism—TPI1—esophageal cancer	0.000182	0.00404	CbGpPWpGaD
Risedronate—FDPS—Metabolism—GSTO1—esophageal cancer	0.000182	0.00404	CbGpPWpGaD
Risedronate—Nausea—Capecitabine—esophageal cancer	0.00018	0.00158	CcSEcCtD
Risedronate—Urticaria—Methotrexate—esophageal cancer	0.000179	0.00158	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000178	0.00395	CbGpPWpGaD
Risedronate—Abdominal pain—Methotrexate—esophageal cancer	0.000178	0.00157	CcSEcCtD
Risedronate—Body temperature increased—Methotrexate—esophageal cancer	0.000178	0.00157	CcSEcCtD
Risedronate—FDPS—Metabolism—ALDOB—esophageal cancer	0.000174	0.00387	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.00017	0.00376	CbGpPWpGaD
Risedronate—FDPS—Metabolism—GAPDH—esophageal cancer	0.000168	0.00372	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000167	0.0037	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CRABP1—esophageal cancer	0.000166	0.00369	CbGpPWpGaD
Risedronate—Hypersensitivity—Methotrexate—esophageal cancer	0.000166	0.00146	CcSEcCtD
Risedronate—Asthenia—Methotrexate—esophageal cancer	0.000162	0.00142	CcSEcCtD
Risedronate—Pruritus—Methotrexate—esophageal cancer	0.000159	0.0014	CcSEcCtD
Risedronate—FDPS—Metabolism—GNG7—esophageal cancer	0.000158	0.00351	CbGpPWpGaD
Risedronate—Diarrhoea—Methotrexate—esophageal cancer	0.000154	0.00136	CcSEcCtD
Risedronate—PTGS2—C-MYB transcription factor network—CREBBP—esophageal cancer	0.000154	0.00341	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000153	0.00339	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000152	0.00337	CbGpPWpGaD
Risedronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—esophageal cancer	0.000151	0.00335	CbGpPWpGaD
Risedronate—Dizziness—Methotrexate—esophageal cancer	0.000149	0.00131	CcSEcCtD
Risedronate—FDPS—Metabolism—ALDH2—esophageal cancer	0.000148	0.00329	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000148	0.00328	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000145	0.00322	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000144	0.0032	CbGpPWpGaD
Risedronate—Vomiting—Methotrexate—esophageal cancer	0.000143	0.00126	CcSEcCtD
Risedronate—Rash—Methotrexate—esophageal cancer	0.000142	0.00125	CcSEcCtD
Risedronate—Dermatitis—Methotrexate—esophageal cancer	0.000142	0.00125	CcSEcCtD
Risedronate—FDPS—Metabolism—GSTT1—esophageal cancer	0.000141	0.00313	CbGpPWpGaD
Risedronate—Headache—Methotrexate—esophageal cancer	0.000141	0.00124	CcSEcCtD
Risedronate—FDPS—Metabolism—CYP2A6—esophageal cancer	0.000139	0.00309	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000139	0.00308	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—TLR4—esophageal cancer	0.000137	0.00304	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—CDKN2A—esophageal cancer	0.000135	0.00299	CbGpPWpGaD
Risedronate—Nausea—Methotrexate—esophageal cancer	0.000134	0.00118	CcSEcCtD
Risedronate—PTGS2—C-MYB transcription factor network—BCL2—esophageal cancer	0.000133	0.00294	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PTGS1—esophageal cancer	0.000132	0.00293	CbGpPWpGaD
Risedronate—FDPS—Metabolism—ENO1—esophageal cancer	0.000132	0.00293	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—NOS2—esophageal cancer	0.00013	0.00289	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PSME2—esophageal cancer	0.00013	0.00289	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PSME1—esophageal cancer	0.00013	0.00289	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000123	0.00273	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000119	0.00264	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.000119	0.00264	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—RB1—esophageal cancer	0.000117	0.00259	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000114	0.00252	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—CCND1—esophageal cancer	0.000114	0.00252	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000113	0.0025	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CYP1B1—esophageal cancer	0.000112	0.00249	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—CDKN1A—esophageal cancer	0.00011	0.00244	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CYP19A1—esophageal cancer	0.000106	0.00234	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—EP300—esophageal cancer	0.000105	0.00232	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000103	0.00228	CbGpPWpGaD
Risedronate—FDPS—Metabolism—HMOX1—esophageal cancer	9.65e-05	0.00214	CbGpPWpGaD
Risedronate—PTGS2—Disease—SLC52A3—esophageal cancer	9.5e-05	0.00211	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	9.46e-05	0.0021	CbGpPWpGaD
Risedronate—FDPS—Metabolism—ABCB1—esophageal cancer	9.26e-05	0.00205	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—MYC—esophageal cancer	9.13e-05	0.00202	CbGpPWpGaD
Risedronate—PTGS2—Disease—KMT2D—esophageal cancer	9.06e-05	0.00201	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	8.95e-05	0.00199	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—CCND1—esophageal cancer	8.67e-05	0.00192	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	8.01e-05	0.00178	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	7.97e-05	0.00177	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—BLVRB—esophageal cancer	7.96e-05	0.00176	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—SLC52A3—esophageal cancer	7.96e-05	0.00176	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	7.11e-05	0.00158	CbGpPWpGaD
Risedronate—PTGS2—Disease—FKBP1A—esophageal cancer	7.03e-05	0.00156	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7e-05	0.00155	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—MYC—esophageal cancer	6.95e-05	0.00154	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	6.87e-05	0.00152	CbGpPWpGaD
Risedronate—PTGS2—Disease—DOCK2—esophageal cancer	6.87e-05	0.00152	CbGpPWpGaD
Risedronate—PTGS2—Disease—WIF1—esophageal cancer	6.87e-05	0.00152	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—EGFR—esophageal cancer	6.8e-05	0.00151	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CA1—esophageal cancer	6.76e-05	0.0015	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—SLC10A2—esophageal cancer	6.76e-05	0.0015	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	6.67e-05	0.00148	CbGpPWpGaD
Risedronate—PTGS2—Disease—CSNK1A1—esophageal cancer	6.34e-05	0.00141	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CREBBP—esophageal cancer	6.19e-05	0.00137	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CA2—esophageal cancer	6.19e-05	0.00137	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	6.05e-05	0.00134	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	5.9e-05	0.00131	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ADH7—esophageal cancer	5.75e-05	0.00128	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PLCE1—esophageal cancer	5.75e-05	0.00128	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—TP53—esophageal cancer	5.71e-05	0.00127	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	5.7e-05	0.00127	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	5.69e-05	0.00126	CbGpPWpGaD
Risedronate—FDPS—Metabolism—NOS3—esophageal cancer	5.54e-05	0.00123	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	5.43e-05	0.0012	CbGpPWpGaD
Risedronate—PTGS2—Disease—ELMO1—esophageal cancer	5.33e-05	0.00118	CbGpPWpGaD
Risedronate—PTGS2—Disease—TPI1—esophageal cancer	5.2e-05	0.00115	CbGpPWpGaD
Risedronate—PTGS2—Disease—GSTO1—esophageal cancer	5.2e-05	0.00115	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PTGS2—esophageal cancer	5.07e-05	0.00112	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ADH1B—esophageal cancer	5.04e-05	0.00112	CbGpPWpGaD
Risedronate—PTGS2—Disease—ALDOB—esophageal cancer	4.99e-05	0.00111	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—TYMP—esophageal cancer	4.82e-05	0.00107	CbGpPWpGaD
Risedronate—PTGS2—Disease—HIST1H2BM—esophageal cancer	4.8e-05	0.00107	CbGpPWpGaD
Risedronate—PTGS2—Disease—GAPDH—esophageal cancer	4.8e-05	0.00107	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	4.73e-05	0.00105	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP26A1—esophageal cancer	4.69e-05	0.00104	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	4.63e-05	0.00103	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ALOX15—esophageal cancer	4.57e-05	0.00101	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—TPI1—esophageal cancer	4.36e-05	0.000967	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTO1—esophageal cancer	4.36e-05	0.000967	CbGpPWpGaD
Risedronate—PTGS2—Disease—XIAP—esophageal cancer	4.24e-05	0.000941	CbGpPWpGaD
Risedronate—FDPS—Metabolism—EP300—esophageal cancer	4.21e-05	0.000935	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ALDOB—esophageal cancer	4.18e-05	0.000927	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GAPDH—esophageal cancer	4.02e-05	0.000892	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	4.02e-05	0.00089	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CRABP1—esophageal cancer	3.99e-05	0.000884	CbGpPWpGaD
Risedronate—PTGS2—Disease—B2M—esophageal cancer	3.94e-05	0.000875	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.88e-05	0.000861	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GNG7—esophageal cancer	3.79e-05	0.000841	CbGpPWpGaD
Risedronate—PTGS2—Disease—ENO1—esophageal cancer	3.78e-05	0.000839	CbGpPWpGaD
Risedronate—PTGS2—Disease—PSME1—esophageal cancer	3.73e-05	0.000826	CbGpPWpGaD
Risedronate—PTGS2—Disease—PSME2—esophageal cancer	3.73e-05	0.000826	CbGpPWpGaD
Risedronate—PTGS2—Disease—CALR—esophageal cancer	3.58e-05	0.000793	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ALDH2—esophageal cancer	3.55e-05	0.000788	CbGpPWpGaD
Risedronate—PTGS2—Disease—FBXW7—esophageal cancer	3.46e-05	0.000767	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTT1—esophageal cancer	3.38e-05	0.00075	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP2A6—esophageal cancer	3.34e-05	0.000741	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.33e-05	0.000738	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ENO1—esophageal cancer	3.17e-05	0.000702	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PTGS1—esophageal cancer	3.17e-05	0.000702	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PSME1—esophageal cancer	3.12e-05	0.000692	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PSME2—esophageal cancer	3.12e-05	0.000692	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PIK3CA—esophageal cancer	3.12e-05	0.000691	CbGpPWpGaD
Risedronate—PTGS2—Disease—TGFBR2—esophageal cancer	2.8e-05	0.00062	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP1B1—esophageal cancer	2.69e-05	0.000597	CbGpPWpGaD
Risedronate—PTGS2—Disease—SMAD4—esophageal cancer	2.65e-05	0.000587	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP19A1—esophageal cancer	2.53e-05	0.000561	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—HMOX1—esophageal cancer	2.31e-05	0.000512	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.27e-05	0.000503	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ABCB1—esophageal cancer	2.22e-05	0.000492	CbGpPWpGaD
Risedronate—PTGS2—Disease—HIF1A—esophageal cancer	2.17e-05	0.00048	CbGpPWpGaD
Risedronate—PTGS2—Disease—NOS2—esophageal cancer	1.97e-05	0.000437	CbGpPWpGaD
Risedronate—PTGS2—Disease—NOTCH1—esophageal cancer	1.95e-05	0.000433	CbGpPWpGaD
Risedronate—PTGS2—Disease—CREBBP—esophageal cancer	1.77e-05	0.000392	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.68e-05	0.000372	CbGpPWpGaD
Risedronate—PTGS2—Disease—NOS3—esophageal cancer	1.58e-05	0.000351	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CREBBP—esophageal cancer	1.48e-05	0.000329	CbGpPWpGaD
Risedronate—PTGS2—Disease—ERBB2—esophageal cancer	1.48e-05	0.000329	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NOS3—esophageal cancer	1.33e-05	0.000294	CbGpPWpGaD
Risedronate—PTGS2—Disease—CDKN1A—esophageal cancer	1.27e-05	0.000281	CbGpPWpGaD
Risedronate—PTGS2—Disease—EP300—esophageal cancer	1.21e-05	0.000267	CbGpPWpGaD
Risedronate—PTGS2—Disease—MYC—esophageal cancer	1.05e-05	0.000233	CbGpPWpGaD
Risedronate—PTGS2—Disease—EGFR—esophageal cancer	1.03e-05	0.000228	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—EP300—esophageal cancer	1.01e-05	0.000224	CbGpPWpGaD
Risedronate—PTGS2—Disease—PIK3CA—esophageal cancer	8.92e-06	0.000198	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PIK3CA—esophageal cancer	7.47e-06	0.000166	CbGpPWpGaD
